Cellectis Soars On Transformative Tie-Up With AstraZeneca
The French biotech’s money concerns are over after a lucrative gene editing deal with AstraZeneca brings in an initial cash commitment of $245m and the possibility of many millions more.
The French biotech’s money concerns are over after a lucrative gene editing deal with AstraZeneca brings in an initial cash commitment of $245m and the possibility of many millions more.